Bonds v. MICHAEL LEAVITT

647 F. Supp. 2d 541, 2009 U.S. Dist. LEXIS 72287, 2009 WL 2525469
CourtDistrict Court, D. Maryland
DecidedAugust 13, 2009
DocketCivil RWT 07-2426
StatusPublished
Cited by4 cases

This text of 647 F. Supp. 2d 541 (Bonds v. MICHAEL LEAVITT) is published on Counsel Stack Legal Research, covering District Court, D. Maryland primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Bonds v. MICHAEL LEAVITT, 647 F. Supp. 2d 541, 2009 U.S. Dist. LEXIS 72287, 2009 WL 2525469 (D. Md. 2009).

Opinion

MEMORANDUM OPINION

ROGER W. TITUS, District Judge.

Congress enacted Title VII of the Civil Rights Act of 1964 to ensure that employees are treated fairly in the workplace without regard to their age, sex, race, and physical characteristics, among others. These vital protections are designed to ensure that employees are evaluated on the basis of their merit as opposed as to their immutable characteristics. The Civil Service Reform Act provides that a number of factors are to be considered in conjunction with a decision to discipline or terminate a federal employee in order to ensure that (1) the action is proportional to the employee’s conduct; (2) employees are subject to consistent criteria and decision-making processes; and (3) there is transparency for what may be a life-altering *546 decision. Last, but not least, the Whistle-blower Protection Act seeks to provide protection to those employees who go above and beyond the call of duty to report abuses and, in doing so, risk their livelihood.

Congress sought to create a broad shield of protection in these three statutes that would immunize employees from any discrimination, retaliation, or arbitrary decisionmaking. The substantial protections offered by these statutes are subject to important standards regarding the inferences and burdens applicable to the assertion of a claim. In its wisdom, Congress recognized that not every decision or action that affects an employee or with which an employee disagrees is actionable. Thus, courts interpreting and applying theses statutes and the cases that interpret them must draw a distinction between personality clashes and discriminatory or retaliatory animus, between honestly-held beliefs and reasons for actions taken and pretext, and between asserting one’s beliefs and true whistleblowing.

Plaintiff Duane R. Bonds, M.D. has filed a Complaint alleging that Defendants violated the provisions of Title VII, the Whistleblower Protection Act, and the Civil Service Reform Act in removing her as the Project Officer from two medical studies and then removing her from federal service. The Court will address each one of her contentions below.

I. BACKGROUND

A. FACTUAL BACKGROUND

Dr. Bonds is an African-American, female doctor, who has dedicated her career to combating sickle cell disease 1 and other medical disorders that severely impact fetal and maternal health. (Pl.’s Ex. 1 ¶¶ 1, 5). She has achieved recognition in the research and understanding of sickle cell disease. (PL’s Ex. 2 OSC Report Summary 2). In 1990, she left private practice and academia to become the Deputy Chief of the Sickle Cell Disease Branch of the Division of Blood Diseases and Resources (“DBDR”), a division of the National Heart, Lung, and Blood Institute (“NHLBI”) of the National Institutes of Health (“NIH”). (PL’s Ex. 148 at 1). From 1990 until October 24, 2006, Dr. Bonds was employed as a medical officer in DBDR. Id. She was the Project Officer (“PO”) for two clinical trials called “SWiTCH” and “BABY HUG.” (Defs Ex. 1 at 1). Her first-line supervisor was Dr. *547 Blaine Moore 2 and her second-line supervisor was Dr. Charles Peterson. Id. at 2-3. From 1997 to 2004, Dr. Bonds received positive performance reviews, within-pay-grade increases, and awards for her merit and service. (Pl.’s Ex. 3 at 1-54; Pl.’s Ex. 15 at 2).

In October of 1999, Dr. Bonds filed an EEO complaint against Dr. Peterson (later resolved through the NIH Ombudsman office) in which she alleged that he sexually harassed her by requesting that she share a hotel room with him during an overnight business trip and that her refusal to do so resulted in his “interfer[enee] with [her] professional duties.” (Pl.’s Ex. 1 ¶ 57).

Dr. Peterson later removed Dr. Bonds from her position as NHLBI’s Sickle Cell Disease Group Leader, and Dr. Bonds filed a second EEO complaint in March, 2003. See EEOC No. 120-2004-00176X; Agency No. NHLBI_2003-0002. The NHLBI resolved the complaint by creating a new position called the Division of Blood Diseases and Resources Sickle Cell Coordinator, and allowing Dr. Bonds to take that position. (Pl.’s Ex. 1 ¶ 50).

As noted above, Dr. Bonds was the Project Officer during this time for two clinical trials called “SWiTCH” and “BABY HUG.” (Pl.’s Ex. 1 ¶ 11). The SWiTCH clinical trial studied the effect of the drug Hydroxyurea on infants who have suffered a stroke. (Def. Ex. 1 at 6). The BABY HUG clinical trial studied the use of Hydroxyurea in infants to ascertain if this drug could prevent the onset of end-organ damage, a major source of morbidity and mortality in sickle cell disease patients. (Def. Ex. 1 at 6).

Discovery of the Immortalized Cell Lines

Dr. Bonds alleges that, in September 2005, she discovered that Dr. Russell Ware, who was a principal investigator in the BABY HUG clinical trial, had obtained genetic material from the blood samples of the BABY HUG infant participants and used them to clone immortalized cell lines 3 *548 without the consent or knowledge of the infants’ parents or guardians. (Def. Ex. 1 at 1-10). Dr. Bonds alleges that the test subjects were all African Americans, and that Dr. Ware was harvesting the genetic material without the consent of the subjects. (Pl.’s Ex. 14 at 14-15). On September 6, 2005, Dr. Bonds wrote in an e-mail to Dr. Ware that she was “very dismayed” over his creation of the immortalized cell lines because “NHLBI did not authorize this work, it is not in the protocol, and the work is not specifically mentioned in the consent forms” and she instructed that he “destroy these cell lines immediately.” (PL’s Ex. 6). Dr. Bonds then brought her concerns before the Data and Safety Monitoring Board (“DSMB”). (PL’s Ex. 4 at A-18). The DSMB, which is charged with safeguarding the interests of study participants, ordered on October 5, 2005 that the cell lines be destroyed. (PL’s Ex. 9; PL’s Ex. 4 at A-18). On October 18, 2005, Dr. Bonds and Dr. Peterson met with Dr. Elizabeth Nabel, the Director of NHLBI, to discuss the cell lines. (PL’s Ex. 1 ¶ 21). Initially, Dr. Nabel supported the position of Dr. Bonds, and a decision was made to support the destruction of the immortalized cell lines Dr. Ware had created. (PL’s Ex. 4 at A-3).

The decision to destroy the cell lines, however, was left to the individual Internal Review Boards (“IRBs”) at BABY HUG clinical sites at each medical center and/or research hospital that was involved in the study. (PL’s Ex. 4 at 8, 14-16). Some IRBs chose to seek consent from the study participants for the creation of these lines, while others chose to interpret the existing consent forms as sufficient to permit the creation of these cell lines. Id.

Dr. Ware contends that Dr. Bonds was fully aware that the cell lines were being created and that she “readily agreed” to their creation. (PL’s Ex. 4 at A-12). He states that he discussed the cell lines at length with Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Thorn v. Sebelius
766 F. Supp. 2d 585 (D. Maryland, 2011)
Bonds v. Leavitt
629 F.3d 369 (Fourth Circuit, 2011)
Capezano v. Arcor Saic
743 F. Supp. 2d 71 (D. Puerto Rico, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
647 F. Supp. 2d 541, 2009 U.S. Dist. LEXIS 72287, 2009 WL 2525469, Counsel Stack Legal Research, https://law.counselstack.com/opinion/bonds-v-michael-leavitt-mdd-2009.